gk5 Antibody

What is GK5 and what are its primary functions in human physiology?

GK5 (Glycerol kinase 5, also known as putative glycerol kinase 5) belongs to the FGGY kinase family and is involved in glycerol metabolism. It catalyzes the phosphorylation of glycerol by ATP, yielding ADP and glycerol-3-phosphate . GK5 has three isoforms produced by alternative splicing with the molecular weights of 59 kDa, 34 kDa, and 28 kDa . While GK5 mRNA is detected in numerous tissues, protein expression appears to be tissue-specific, with notable expression in sebaceous glands adjacent to hair follicles . Recent research has also implicated GK5 in cancer biology, particularly in gefitinib resistance in non-small cell lung cancer .

What techniques can be used to detect GK5 expression in tissue samples?

Multiple techniques can be employed to detect GK5 expression:

• Western Blotting (WB): Useful for detecting GK5 protein expression levels and distinguishing between isoforms. Recommended dilutions range from 1:500-1:2000 .

• Immunohistochemistry (IHC): Effective for localizing GK5 expression in tissue sections. Recommended dilutions range from 1:30-1:150 .

• Immunofluorescence (IF): Allows visualization of cellular localization. GK5 has been observed primarily in the cytoplasm of cells .

• Real-time PCR: For detection of GK5 mRNA expression levels .

• Exosomal mRNA detection: Specialized techniques like tethered cationic lipoplex nanoparticle (TCLN) biochip have been used to detect exosomal mRNA of GK5 in plasma samples .

What are the key considerations when selecting a GK5 antibody for research?

When selecting a GK5 antibody, researchers should consider:

• Antibody type: Polyclonal antibodies, like those described in the search results, offer high sensitivity but may have batch-to-batch variation .

• Host species: Most commercial GK5 antibodies are produced in rabbits .

• Validated applications: Ensure the antibody has been validated for your specific application (WB, IHC, IF) .

• Reactivity: Confirm the antibody recognizes GK5 in your species of interest. Available antibodies react with human GK5, with some also recognizing mouse and rat GK5 .

• Epitope region: Consider whether you need an antibody that recognizes a specific region or isoform of GK5. Some antibodies target the N-terminus .

• Storage conditions: Most GK5 antibodies require storage at -20°C and are shipped with ice packs .

How does GK5 contribute to gefitinib resistance in non-small cell lung cancer?

GK5 has been identified as a key mediator of gefitinib resistance in non-small cell lung cancer (NSCLC). Research shows:

• Upregulation in resistant cells: GK5 is significantly upregulated in gefitinib-resistant lung adenocarcinoma cells (PC9R and H1975) compared to gefitinib-sensitive PC9 cells .

• Exosomal marker: Exosomal mRNA of GK5 is significantly higher in the plasma of patients with gefitinib-resistant adenocarcinoma compared to gefitinib-sensitive patients, suggesting potential as a biomarker .

• Mechanistic pathway: GK5 confers gefitinib resistance through the SREBP1/SCD1 signaling pathway .

• Experimental validation:

  • Overexpression of GK5 in gefitinib-sensitive PC9 cells induced drug resistance

  • Silencing GK5 in gefitinib-resistant PC9R cells enhanced gefitinib-induced apoptosis

  • GK5 knockdown induced mitochondrial damage, caspase activation, cell cycle arrest, and apoptosis

These findings suggest GK5 could be a novel therapeutic target for treating NSCLC with resistance to EGFR tyrosine kinase inhibitors .

What is the relationship between GK5 and the SREBP signaling pathway?

GK5 plays a significant role in regulating the SREBP (Sterol Regulatory Element-Binding Protein) signaling pathway:

• Physical interactions: GK5 associates with both SREBP-1 and SREBP-2, with the C-terminal regulatory domains of SREBPs being necessary and sufficient for interaction with GK5 .

• Interaction strength: The apparent strengths of associations between GK5 and SREBP-1/-2 are much greater than between GK (glycerol kinase) and SREBP-1/-2 .

• Mechanism of action:

  • GK5 interacts with SREBP-1 and SREBP-2 in a kinase-independent manner

  • This interaction inhibits the proteolytic processing of SREBPs

  • Despite binding to the C-terminal domain of SREBPs, GK5 does not block their binding to SCAP (SREBP cleavage-activating protein)

• Functional significance: This relationship is important in regulating lipid biosynthesis, particularly in sebaceous glands where GK5 is preferentially expressed .

The GK5-SREBP interaction represents a skin-specific regulatory mechanism for SREBP processing and lipid biosynthesis .

What methodological considerations should be addressed when using GK5 antibodies for Western blotting?

When using GK5 antibodies for Western blotting, researchers should consider:

• Expected band size vs. observed bands: The calculated molecular weight of GK5 is 59 kDa, but the observed molecular weight may differ. This discrepancy can result from:

  • Post-translational modifications

  • Different protein isoforms (59 kDa, 34 kDa, and 28 kDa)

  • Proteolytic cleavage during sample preparation

• Sample preparation: Whole-cell lysates from relevant tissues (particularly skin samples) should be prepared with appropriate protease inhibitors to prevent degradation .

• Antibody dilution optimization: Starting with recommended dilutions (1:500-1:2000) and optimizing based on signal-to-noise ratio .

• Controls:

  • Positive control: Human breast tissue has been verified for some GK5 antibodies

  • Negative control: Consider tissues known not to express GK5 protein or use GK5 knockout samples when available

• Detection method: Choose an appropriate secondary antibody and detection system based on expected expression levels.

• Verification of specificity: Cross-validation with different GK5 antibodies or complementary techniques like immunoprecipitation can help confirm specificity .

How can researchers effectively design experiments to study GK5's role in cancer drug resistance?

To effectively study GK5's role in cancer drug resistance, researchers should consider:

• Cell line selection:

  • Drug-sensitive cell lines (e.g., PC9 for gefitinib studies)

  • Drug-resistant cell lines (e.g., PC9R, H1975 for gefitinib resistance)

  • Paired cell lines developed through gradual drug exposure

• Gene manipulation approaches:

  • Overexpression: Lentivirus vectors carrying the complete open reading frame of GK5

  • Knockdown: shRNA targeting GK5 (shGK5-1, shGK5-2)

  • Verification of manipulation efficiency by qRT-PCR and Western blot

• Functional assays:

  • Cell viability: CCK-8 assay with varying drug concentrations

  • Apoptosis: Annexin V-APC/DAPI double staining followed by flow cytometry

  • Cell cycle analysis

  • Mitochondrial membrane potential: JC-1 dye

• Mechanistic studies:

  • Pathway analysis: Focus on SREBP1/SCD1 signaling

  • Protein-protein interactions: Co-immunoprecipitation to study GK5 interactions

  • Phosphorylation assays to assess kinase activity

• In vivo validation:

  • Xenograft models with GK5-manipulated cells

  • Patient-derived xenografts

  • Assessment of tumor growth and response to therapy

• Clinical correlation:

  • Analysis of GK5 expression in patient samples

  • Correlation with treatment response

  • Exosomal mRNA analysis as potential biomarker

What techniques can be used to study the interaction between GK5 and SREBP proteins?

Several techniques can be employed to study GK5-SREBP interactions:

• Co-immunoprecipitation (Co-IP):

  • Express tagged proteins (e.g., FLAG-tagged SREBP-1/2 and HA-tagged GK5) in suitable cell lines (HEK293T, 3T3-L1, HepG2)

  • Immunoprecipitate with anti-tag antibodies

  • Analyze co-precipitated proteins by Western blotting

• Domain mapping:

  • Generate truncated versions of GK5 and SREBPs

  • Determine minimal interaction domains through Co-IP

  • Research has shown that the N-terminal FGGY domains of GK and GK5 are sufficient to mediate interaction, and the C-terminal regulatory domains of SREBP-1 and SREBP-2 are necessary for interaction with GK5

• Functional assays:

  • Measure SREBP processing in the presence/absence of GK5

  • Assess impact of GK5 mutants lacking kinase activity

  • Quantify downstream target gene expression

• Competitive binding assays:

  • Determine if GK5 competes with other SREBP-interacting proteins

  • Studies have shown GK5 does not interfere with SCAP-SREBP interaction

• Structural analysis:

  • X-ray crystallography or cryo-EM to determine interaction interfaces

  • Similar approaches have been successful for studying antibody-protein interactions

• Visualization techniques:

  • Fluorescence resonance energy transfer (FRET)

  • Bioluminescence resonance energy transfer (BRET)

  • Proximity ligation assay (PLA) for visualizing endogenous interactions

How does the observed molecular weight of GK5 relate to its functional isoforms and what implications does this have for antibody selection?

The relationship between GK5's observed molecular weight and its functional isoforms has important implications for antibody selection:

• GK5 isoforms:

  • GK5 has three isoforms produced by alternative splicing with molecular weights of 59 kDa (GK5-v2), 34 kDa, and 28 kDa

  • Immunoblot analysis of whole-skin lysates revealed a single band of ~60 kDa corresponding to GK5-v2

• Tissue-specific expression patterns:

  • While GK5 mRNA is detected in numerous tissues, the 60-kDa GK5 protein band was present only in skin tissue

  • Immunostaining demonstrated localization primarily to sebaceous glands

• Implications for antibody selection:

  • Epitope location: Antibodies targeting different regions may detect specific isoforms

  • The N-terminal antibody used in some studies detected a single 60-kDa band in skin

  • Some commercial antibodies are generated against full-length fusion proteins

• Experimental considerations:

  • Western blotting may show bands inconsistent with expectations due to:

    • Post-translational modifications

    • Protein degradation

    • Cross-reactivity

  • Verification using multiple antibodies or complementary techniques is recommended

• Functional relevance:

  • Different isoforms may have distinct functions or subcellular localizations

  • GK5-v1 and GK5-v2 both interact with GK isoforms

  • Kinase activity appears necessary for normal hair growth but dispensable for interaction with SREBP-1/-2

When selecting antibodies, researchers should consider which isoform(s) they aim to detect and choose antibodies with appropriate epitope specificity.

What are the optimal conditions for storing and handling GK5 antibodies?

Optimal storage and handling conditions for GK5 antibodies include:

• Storage temperature: Store at -20°C. Most GK5 antibodies are stable for up to 12 months after shipment when properly stored .

• Formulation: Typically supplied in phosphate buffered solution (pH 7.4) containing stabilizers:

  • Many commercial formulations contain 50% glycerol to prevent freeze-thaw damage

  • Some may include 0.05% stabilizer

• Shipping conditions: Usually shipped with ice packs. Upon receipt, immediately store at the recommended temperature .

• Aliquoting: For frequent use, aliquot to avoid repeated freeze-thaw cycles which can compromise antibody performance .

• Working dilution preparation: Dilute only the amount needed for immediate use, typically in:

  • For WB: 5% non-fat milk or BSA in TBST

  • For IHC/IF: Antibody dilution buffer with appropriate blocking reagents

• Handling precautions:

  • Avoid contamination

  • Centrifuge briefly before opening vial

  • Do not vortex antibody solutions vigorously

  • Use sterile techniques when handling

Following these guidelines will help maintain antibody performance and extend shelf-life.

What troubleshooting approaches can be used when GK5 antibodies produce unexpected results?

When GK5 antibodies produce unexpected results, consider these troubleshooting approaches:

• Unexpected band size in Western blot:

  • Problem: Observed band size differs from calculated 59 kDa

  • Solutions:

    • Consider isoforms (59 kDa, 34 kDa, 28 kDa)

    • Check for post-translational modifications

    • Verify antibody specificity using positive controls

• Weak or no signal:

  • Problems: Insufficient protein, antibody degradation, suboptimal conditions

  • Solutions:

    • Increase protein loading

    • Use fresh antibody aliquot

    • Optimize antibody concentration (try 1:500-1:2000 for WB, 1:30-1:150 for IHC)

    • Extend incubation time or use more sensitive detection methods

• High background:

  • Problems: Insufficient blocking, excessive antibody concentration, cross-reactivity

  • Solutions:

    • Optimize blocking conditions

    • Further dilute primary and secondary antibodies

    • Increase wash steps duration and frequency

    • Use alternative blocking reagents

• Inconsistent results across experiments:

  • Problems: Batch-to-batch variation, sample degradation, protocol inconsistencies

  • Solutions:

    • Use antibodies from a consistent lot when possible

    • Standardize sample preparation protocols

    • Include appropriate controls in each experiment

    • Consider antibody validation using knockdown/knockout samples

• Tissue-specific detection issues:

  • Problem: GK5 protein shows tissue-specific expression despite mRNA being detected in multiple tissues

  • Solutions:

    • Use tissues with confirmed GK5 expression (skin, sebaceous glands) as positive controls

    • Optimize fixation and antigen retrieval for IHC/IF

    • Consider using verified samples (human breast for WB, human esophagus cancer for IHC)

• Cross-reactivity with other FGGY family members:

  • Problem: Antibody might detect related proteins

  • Solutions:

    • Perform specificity controls using recombinant proteins

    • Consider using antibodies raised against unique epitopes of GK5

How can single-chain Fv constructs improve structural studies of antibody-antigen interactions?

Single-chain Fv (scFv) constructs can significantly improve structural studies of antibody-antigen interactions, as demonstrated in recent research:

• Addressing preferred orientation bias:

  • The use of scFv instead of Fab constructs improved the quality of cryo-EM maps of antibody-protein complexes

  • This improvement resulted from preventing preferred orientations induced by Fab orientation

• Resolution enhancement:

  • Local refinement focused on antibody-antigen interfaces achieved resolutions of 3.27 Å using scFv constructs

  • This allowed for detailed visualization of interaction between binding partners

• Practical advantages:

  • Smaller size compared to Fab or full IgG

  • Enhanced stability and solubility

  • More uniform particle distribution in cryo-EM specimens

  • Can be expressed in bacterial systems (lower cost, higher yield)

• Design considerations for scFv studies:

  • Linker design is critical (typically (Gly4Ser)3)

  • Expression systems must be optimized

  • Stability testing is essential before structural studies

• Stoichiometric insights:

  • scFv constructs allow more accurate determination of binding stoichiometry

  • Mass photometry experiments have shown different binding patterns between scFv/Fab (1:3) and IgG (1:2) to trimeric targets

• Application to GK5 antibody research:

  • This approach could be valuable for structural studies of GK5 antibodies bound to different GK5 isoforms

  • Could help identify epitopes and distinguish between isoform-specific interactions

What approaches can be used to validate the specificity of GK5 antibodies?

Validating antibody specificity is crucial for reliable experimental results. For GK5 antibodies, consider these validation approaches:

• Genetic validation:

  • Use GK5 knockout/knockdown models:

    • Immunoblot analysis of skin lysates from wild-type vs. GK5 knockout mice showed absence of the ~60 kDa band in knockout samples

    • siRNA or shRNA knockdown in relevant cell lines

• Peptide competition assays:

  • Pre-incubate antibody with excess immunizing peptide

  • Compare signal with and without peptide competition

  • Specific signals should be blocked by the peptide

• Multiple antibody validation:

  • Use antibodies targeting different GK5 epitopes

  • Compare results across antibodies from different sources

  • Consistent results increase confidence in specificity

• Recombinant protein controls:

  • Express tagged GK5 in cell lines

  • Verify antibody detection of the tagged protein

  • Use as positive control in subsequent experiments

• Cross-reactivity assessment:

  • Test antibody against related FGGY family members

  • Assess potential cross-reactivity with GK, which interacts with GK5

• Application-specific validation:

  • For WB: Confirm band size corresponds to expected isoforms (~59, 34, 28 kDa)

  • For IHC/IF: Compare staining pattern with known GK5 localization (sebaceous glands)

  • Include relevant controls (GK5-negative tissues or cells)

• Correlation of protein with mRNA expression:

  • Compare protein detection with qRT-PCR results

  • Note that GK5 mRNA is found in multiple tissues, but protein may be more restricted

How can GK5 antibodies be used to study the role of GK5 in cancer drug resistance mechanisms?

GK5 antibodies can be instrumental in studying cancer drug resistance through multiple experimental approaches:

• Expression analysis in clinical samples:

  • IHC can be used to evaluate GK5 expression in tumor biopsies before and after treatment

  • Compare expression patterns between drug-sensitive and drug-resistant tumors

  • Correlate expression levels with patient outcomes and treatment response

• Mechanistic studies in cell lines:

  • WB to quantify GK5 protein levels in sensitive vs. resistant cell lines

    • Gefitinib-sensitive PC9 vs. gefitinib-resistant PC9R and H1975 cells show differential GK5 expression

  • IF to examine subcellular localization changes during resistance development

  • Co-IP to investigate protein interactions with SREBP1/SCD1 pathway components

• Functional validation experiments:

  • After GK5 knockdown or overexpression, use antibodies to:

    • Confirm manipulation success

    • Monitor downstream effectors

    • Assess pathway activation status

  • Combine with functional assays (viability, apoptosis) to link expression with phenotype

• Biomarker development:

  • Validate exosomal GK5 mRNA findings at the protein level

  • Develop assays to detect GK5 in liquid biopsies

  • Evaluate GK5 as a predictive biomarker for EGFR-TKI resistance

• Therapeutic targeting validation:

  • Use antibodies to confirm target engagement of GK5-directed therapies

  • Monitor GK5 expression changes in response to combination treatments

  • Assess pathway modulation during therapeutic interventions

By employing GK5 antibodies in these contexts, researchers can gain comprehensive insights into GK5's role in drug resistance mechanisms and potentially develop strategies to overcome resistance.

What are the implications of GK5's role in SREBP processing for metabolic research?

GK5's role in SREBP processing has significant implications for metabolic research:

• Tissue-specific regulation of lipid metabolism:

  • GK5 represents a skin-specific regulator of SREBP processing and lipid biosynthesis

  • This tissue specificity suggests specialized metabolic control mechanisms in different organs

  • Research implications: Investigating tissue-specific metabolic regulators could reveal new therapeutic targets

• Connection between glycerol metabolism and lipid synthesis:

  • GK5 links glycerol phosphorylation to SREBP-mediated lipid synthesis

  • This connection integrates two key metabolic pathways

  • Research implications: Understanding this crosstalk could provide insights into metabolic disorders

• Non-enzymatic functions of metabolic enzymes:

  • GK5's interaction with SREBPs is independent of its kinase activity

  • This demonstrates that metabolic enzymes can have regulatory roles beyond their catalytic functions

  • Research implications: Investigating protein-protein interactions of metabolic enzymes may reveal novel regulatory mechanisms

• Sebaceous gland biology:

  • GK5's localization to sebaceous glands suggests a specific role in sebum production

  • Sebum composition and production are dysregulated in conditions like acne

  • Research implications: Studying GK5-SREBP interactions could lead to new approaches for treating sebaceous gland disorders

• Cancer metabolism:

  • Altered lipid metabolism is a hallmark of cancer

  • GK5's role in gefitinib resistance connects metabolic adaptation to drug sensitivity

  • Research implications: Targeting GK5-SREBP interaction could sensitize resistant cancer cells to therapy

• Experimental approaches:

  • Measure SREBP target gene expression in GK5-manipulated systems

  • Assess lipid profiles in tissues/cells with altered GK5 expression

  • Investigate metabolic flux using isotope-labeled substrates

  • Develop small molecule inhibitors of GK5-SREBP interaction

Understanding these implications requires specialized tools, including well-characterized GK5 antibodies for detecting expression patterns and protein interactions across different experimental contexts.

What considerations should be made when designing immunofluorescence experiments using GK5 antibodies?

When designing immunofluorescence (IF) experiments with GK5 antibodies, consider these important factors:

• Sample preparation:

  • Cell fixation: 4% paraformaldehyde is commonly used for cytoplasmic proteins like GK5

  • Permeabilization: Optimize for cytoplasmic access (0.1-0.5% Triton X-100)

  • Antigen retrieval: May be necessary for tissue sections, particularly for formalin-fixed tissues

• Antibody selection and optimization:

  • Verify IF suitability: Not all GK5 antibodies work well for IF; select antibodies validated for this application

  • Dilution: Start with recommended dilutions (typically higher concentration than for WB) and optimize

  • Incubation conditions: Temperature (4°C overnight or room temperature) and time affect staining quality

• Controls:

  • Positive control: Include cells/tissues known to express GK5 (sebaceous glands in skin sections)

  • Negative control: Include GK5-negative samples or secondary-only controls

  • Knockdown validation: If possible, include GK5 knockdown samples

• Subcellular localization expectations:

  • GK5 is primarily cytoplasmic in transfected NIH 3T3 cells

  • Compare subcellular distribution with known patterns

  • Consider co-staining with organelle markers to confirm localization

• Multiplexing considerations:

  • Co-staining with other proteins: Choose compatible primary antibodies (different species)

  • When studying GK5 interaction with SREBP1/2, consider co-staining approaches

  • Select secondary antibodies with non-overlapping fluorophores

• Image acquisition settings:

  • Optimize exposure to avoid saturation

  • Use consistent settings between samples for quantitative comparisons

  • Z-stack imaging may be necessary for three-dimensional analysis

  • Consider super-resolution techniques for co-localization studies

• Quantification approaches:

  • Define appropriate parameters (intensity, area, co-localization)

  • Use standardized analysis methods

  • Blind the analysis to prevent bias